318 related articles for article (PubMed ID: 23226148)
21. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
22. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
23. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
24. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders.
Bhatt ST; Bednarski JJ
Front Immunol; 2020; 11():1988. PubMed ID: 33013851
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
26. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
27. Correlation of Hsp70-1 and Hsp70-2 gene expression with the degree of graft-versus-host reaction in a rat skin explant model.
Novota P; Sviland L; Zinöcker S; Stocki P; Balavarca Y; Bickeböller H; Rolstad B; Wang XN; Dickinson AM; Dressel R
Transplantation; 2008 Jun; 85(12):1809-16. PubMed ID: 18580475
[TBL] [Abstract][Full Text] [Related]
28. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
29. [Extracellular adenosine is a therapeutic target for limiting graft-versus-host disease and enhancing the graft-versus-tumor effect against hematopoietic malignancy].
Tsukamoto H
Yakugaku Zasshi; 2014; 134(10):1021-7. PubMed ID: 25274211
[TBL] [Abstract][Full Text] [Related]
30. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.
Feng X; Hui KM; Younes HM; Brickner AG
Trends Immunol; 2008 Dec; 29(12):624-32. PubMed ID: 18952501
[TBL] [Abstract][Full Text] [Related]
31. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution.
Abdel-Azim H; Elshoury A; Mahadeo KM; Parkman R; Kapoor N
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1437-1446. PubMed ID: 28495643
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
[TBL] [Abstract][Full Text] [Related]
33. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.
Hobo W; Broen K; van der Velden WJ; Greupink-Draaisma A; Adisty N; Wouters Y; Kester M; Fredrix H; Jansen JH; van der Reijden B; Falkenburg JH; de Witte T; Preijers F; Schattenberg T; Feuth T; Blijlevens NM; Schaap N; Dolstra H
Biol Blood Marrow Transplant; 2013 Feb; 19(2):274-82. PubMed ID: 23022467
[TBL] [Abstract][Full Text] [Related]
34. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
35. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
[TBL] [Abstract][Full Text] [Related]
36. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
[TBL] [Abstract][Full Text] [Related]
37. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
Ito M; Shizuru JA
Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
[TBL] [Abstract][Full Text] [Related]
38. [Immunologic reconstitution after hematopoietic stem cell transplantation--parameters of monitoring and current methods of its evaluation].
Vojvodić S
Med Pregl; 2002; 55(7-8):293-8. PubMed ID: 12434674
[TBL] [Abstract][Full Text] [Related]
39. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.
Ogonek J; Kralj Juric M; Ghimire S; Varanasi PR; Holler E; Greinix H; Weissinger E
Front Immunol; 2016; 7():507. PubMed ID: 27909435
[TBL] [Abstract][Full Text] [Related]
40. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
